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Abstract
Background: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast
cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth
factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect
of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes
of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three
cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility.
Methods: A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1wt
or ESR1Y537S, modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination
of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT),
or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated
transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess
the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene
expression as a result of the indicated therapies.
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Results: Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease
in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy
further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib,
and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in
the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element
on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an
effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of
RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis
revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops
associated with RAD001.
Conclusions: Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with
fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.
Keywords: Breast cancer, Oestrogen receptor, Neratinib, Everomilus, Endocrine resistance,
Background
Breast cancer (BC) is the most common malignancy in
women, and was responsible for over 522,000 deaths in
2012 [1]. The majority of the BCs at primary diagnosis are
oestrogen receptor (ER)-alpha positive (ER+) and depend
on oestrogen (E) for their growth and progression.
Endocrine therapies targeting oestrogenic stimulation of
tumour growth have been developed clinically, and have
shown success in reducing the mortality of ER+ BC. These
therapies include: tamoxifen, which competes with E for
the ER; fulvestrant (ICI182780), which binds to ER and
targets it for degradation; and aromatase inhibitors (AIs),
which block the conversion of androgens to E [2]. Despite
the initial effectiveness of these approaches, many patients
eventually relapse with either intrinsic or acquired resist-
ance and, in most cases, continue to express ER [3, 4].
Studies suggest that ESR1 mutations within the ligand
binding domain of the receptor and/or cross-talk between
ER and various cellular kinases allow the receptor to
circumvent the need for steroid hormone [5]. In recent
years, emphasis has been placed on co-targeting both the
ER and the phosphatidylinositol-3-kinase/protein kinase
B/mammalian target of rapamycin (PI3K/AKT/mTORC)
pathway, known to phosphorylate and activate ER in a
ligand-independent manner [6], to avoid or reverse these
resistance mechanisms.
The combination of the rapalogue everolimus (RAD001)
with exemestane, as third-line therapy in ER+/ERBB2-ne-
gative patients who relapsed on prior endocrine therapy,
was reported from the BOLERO-2 trial to increase median
progression-free survival (PFS) from 4.1 to 10.6 months
compared with exemestane alone [7]. Nonetheless, it is
clear that blockade of a single protein in a complex signal-
ling cascade, even if a critical downstream effecter, is un-
likely to provide a total or prolonged growth inhibition
partly as a result of early rewiring. For instance, a negative
feedback loop exists downstream in the PI3K/AKT/
mTORC pathway such that mTORC1 inhibition leads to a
reduction in S6 K1 activity, which in turn allows IRS1/2 ex-
pression to be increased with associated enhanced activa-
tion of IGFR1-dependent AKT activity [8]. Furthermore,
mTORC1 blockade has also been shown to induce en-
hanced ERBB2/3 signalling [9], as well as ERK1/2 [8, 10],
creating potential routes of escape negating the
anti-tumour effectiveness of mTORC1 blockade and limit-
ing long-term effectiveness (Fig. 1). This may account for
the short-term clinical remissions and lack of stable
disease, often with rebound growth at the time of further
disease progression. As such, it is rational to explore
targeting of mTORC1 with vertical blockade of growth fac-
tor receptors, such as those governing ERBB signalling
(Fig. 1).
In this study, we assessed the effect of the combined ther-
apy of the mTORC1 inhibitor, RAD001, with additional
co-blockade of ERBB signalling with neratinib, an irrevers-
ible pan-ERBB receptor tyrosine kinase (RTK) inhibitor
[11–13], in human BC cell models of endocrine-sensitive
and -resistant disease with varying ESR1, PIK3CA, and
ERBB2 mutation status. Analysis showed that triple block-
ade of the three signalling nodes had greater efficacy than
monotherapies both in vitro and in vivo and that the triple
combination was well tolerated in a xenograft model.
Methods
Reagents
Primary antibodies against phospho-EGFRtyr1068 (CST-3777),
total-EGFR (CST-2232), phospho-ERBB2tyr1248 (CST-2247),
phospho-ERBB3tyr1222 (CST-4784), total-ERK1/2 (CST-9102),
phospho-AKTser473 (CST-9271), total-AKT (CST-9272),
phospho-S6ser240/244 (CST-5364), total-S6 (CST-2217),
phospho-ERser167 (CST-5587), phospho-Rbser807/811
(CST-8516), CDK4 (CST-2901), and cyclinD1 (CST-2922)
were purchased from Cell Signaling, Inc.; total-ERBB3
(sc-415), ER-alpha (sc-8002, F-10), and PARP (sc-8007) were
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purchased from Santa Cruz; phospho-ERK1/2 and α-tubulin
(T-9026) were obtained from Sigma; and total-ERBB2 was
obtained from Millipore. Secondary antibodies (anti-mouse
and anti-rabbit horseradish peroxidase) were obtained from
Dako. 17β-Oestradiol (E2) and 4-hydroxytamoxifen (4-OHT)
were purchased from Sigma, and fulvestrant (referred to as
ICI) was obtained from Trocis, UK. Neratinib (PB272) was
provided by Puma Biotechnology and Pfizer. Everolimus
(RAD001) was purchased from Selleck. All chemicals, unless
otherwise stated, were purchased from Sigma, UK. All tissue
culture grade plastics were obtained from Nunc, UK.
Tissue culture
The human BC cell lines were obtained from the ATCC
Rockville, USA, or Asterand and authenticity was con-
firmed by STR. Cells were aliquoted to prevent phenotypic
drift and routinely tested for Mycoplasma contamination.
Wild-type (wt)-MCF7, wt-HCC1428, and wt-SUM44 cell
lines were cultured in phenol red-free RPMI medium
supplemented with 10% fetal bovine serum (FBS) and
1 nM E2. MCF7, HCC1428, and SUM44 cells adapted to
long-term E deprivation (LTED) and modelling resistance
to an AI were maintained in phenol red-free RPMI
medium containing 10% dextran charcoal-stripped serum
(DCC) in the absence of E2 [14]. Cells were passaged
twice weekly and fed every 48 to 72 h. MCF7-LTED and
HCC1428-LTED are homozygotes for ESR1wt, whilst
SUM44-LTED are heterozygotes for ESR1Y537S.
Cell proliferation assays
Wt-MCF7, wt-SUM44, wt-HCC1428, and their LTED
derivatives were seeded in 10% DCC medium into 96-well
plates. Cell monolayers were left to acclimatize for 24 h
before treatment with the drug combinations for 6 days
with a treatment change on day 3. Cell viability was
determined using the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega) according to the manufacturer’s
protocol.
Transcription assays
Cell lines were seeded in 24-well plates in DCC medium
and left to acclimatize for 24 h. The following day, trans-
fection was performed using Fugene (Promega) with
0.1 μg of E response element linked luciferase (EREIItk-
luc) and 0.1 μg β-galactosidase (pCH110) reporter con-
structs [15]. Luciferase (Promega) and β-galactosidase
(GalactoStar, Applied Biosystems) activity was measured
using a luminometer.
a b c
Fig. 1 Simplified schematic diagram of the pathways described in this study. a Growth factor signalling (IGFR and ERBB) leads to activation of
PI3K and phosphorylation of AKT. AKT inhibits TCS1/2, resulting in upregulation of mTORC1. In parallel, mTORC1 can also be upregulated by the
RAS-RAF-MEK-ERK signalling pathway. ERK phosphorylates and inactivates TCS2 also leading to mTORC1 activation. S6 K1 activity increases as a
result of mTORC1 activation. S6 K1 suppresses mTORC2 and IRS1. ER is also a target of S6 K1 leading to phosphorylation of serine 167. b Inhibition of
mTORC1 with everolimus suppresses S6 K1 removing the negative feedback loop causing a rise in IRS1 and AKT activity via loss of suppression on
mTORC2. Increased AKT activity suppresses TCS1/2 and increases expression of growth factor receptors (ERBB2/3) enhancing RAS-RAF-ERK signalling.
c The dual blockade of ERBBs (neratinib) and mTORC1 signalling (everolimus) may suppress the two feedback loops described in b. Yellow shows
normal mTORC signalling cascade; blue represents activated proteins; red represents inhibited proteins; dotted lines show loss of normal feedback loops
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Western blotting
Whole cell extracts were generated as described previ-
ously [16]. Equal amounts of protein were resolved by
SDS-PAGE and transferred to nitrocellulose membranes
(Whatman). Antigen-antibody interactions were detected
with Amersham ECL detection reagents (GE Healthcare).
Chromatin immunoprecipitation
Wt-HCC1428 and HCC1428-LTED cells were cross-linked
in 1% formaldehyde at room temperature for 10 min and
then quenched with 125 mM glycine. Samples were then
lysed and sonicated, and chromatin was immunoprecipi-
tated by overnight incubation at 4 °C with ER (HC-20,
sc-546) or IgG antibodies pre-bound with Protein G
magnetic dynabeads (Invitrogen). Chromatin was washed
vigorously with RIPA buffer and reverse cross-linked by an
overnight incubation in elution buffer at 65 °C. DNA was
digested with RNase and Proteinase K, purified, precipi-
tated with phenol chloroform, and eluted in Tris-HCl
pH 8.0. Real-time quantitative polymerase chain reaction
(qPCR) was performed using TFF1 oligos: forward: 5′ GGC
CAT CTC TCA CTA TGA ATC ACT TCT GCA 3′; and
reverse: 5′ GGC AGG CTC TGT TTG CTT AAA GAG
CGT TAG 3′.
Ion torrent
DNA was amplified using Ion AmpliSeq™ Library Kit 2.0
(Life Technologies), then digested, and Ion Xpress™
Barcode adapters ligated and purified with Agencourt
AMPure XP magnetic beads (Beckman Coulter). Librar-
ies were quantified by qPCR using an Ion Library Quan-
tification Kit (Life Technologies), templated on the Ion
OneTouch2 System (Life Technologies) and sequenced
on the Ion PGM System (Life Technologies). Reads were
aligned by the PGM server with standard settings to the
reference genome hg19; samtools v1.2 was used to
calculate the on-target coverage.
IonReporter™ (v4.4) was used for mutation calling (pa-
rameters: Data Quality Stringency = 12, Downsample To
Coverage = 4000, SNP/InDel/MNP Min Cov Each Strand =
50, SNP/InDel/MNP Min Variant Score = 15, SNP/InDel/
MNP Min Coverage = 250, Hotspot Min Variant Score = 6,
Hotspot Min Coverage = 150). All mutations called were
manually reviewed in IGV and included in the analysis if
they had aVAF ≥ 1%.
Human tumour xenografts modelling relapse on AI
therapy
In-vivo studies were carried out in ovariectomized 8- to
12-week-old female BALB/c FOX nude mice in accordance
with Home Office guidelines and approved by the Institute
of Cancer Research Ethics Committee. MCF72a-LTED
tumour xenografts were initiated by the implantation of
cells (107) combined with matrigel (1:1) into the left flank.
Tumours were established in the absence of E. Once
tumours reached a diameter of 7–8 mm, animals were
assigned to treatment groups with no statistically significant
differences in mean volume before treatment. Animals were
treated with either vehicle, fulvestrant administrated
subcutaneously weekly (5 mg/kg in olive oil), neratinib
(40 mg/kg in 0.5% hydroxypropyl methylcellulose (HPMC)/
0.4% Tween 80), or RAD001 (2 mg/kg in 0.5% HPMC/0.4%
Tween 80) administered daily by oral gavage for a total of
41 days. Drugs were supplied alone or in the combinations
indicated. Tumour growth was assessed weekly in all arms
by calliper measurements of the two large diameters.
Volumes were calculated according to the formula: a × b2
× π/6, where a and b are orthogonal tumour diameters.
Tumour volumes were then expressed as mean
fold-change in volume at the start of treatment. The study
operator was blinded to the treatments.
A second short-term study to address changes in gene
expression was performed. Tumours from three mice
per treatment were harvested 6 h post-final drug admin-
istration following 5 full days of therapy. Tumours were
snap frozen in liquid nitrogen for gene expression
analysis.
Immunohistochemical analysis
Tumour fragments were formalin-fixed and
paraffin-embedded. Sections were stained for ER using
anti-ER antibody (6F11, Novocastra, UK) [17].
RNA-seq
Libraries were created after the Ribo-zero rRNA removal
kit (Illumina) using NEBNext Ultra Directional RNA
(NEB) and sequenced using the HiSeq2500 (paired end
100 bp v4 chemistry). Tophat (v2.1) and Cuffdiff (v2.2.1)
[18] with default parameters were used for alignment and
differential expression analysis. Genes which had a
fold-change greater than 50% compared with vehicle in
any condition were mapped to KEGG pathway graphs
using Pathview [19]. Gene set enrichment analysis (GSEA)
[20] was used to identify gene sets that were significantly
up- or downregulated in each treatment. [19]. The data
supporting this study have been deposited in the NCBI
gene expression omnibus (GSE112401).
Statistical analysis
Statistical analysis was performed using Student’s t test
or one-way analysis of variance (ANOVA) with Tukey’s
to adjust for multiple comparisons. For xenograft stu-
dies, overall statistical differences were calculated using
the Wilcoxon signed-rank test if the variance was not
equal and failed the normality test, otherwise paired t
tests were used.
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Results
Effect of RAD001 or neratinib alone or in combination
with endocrine therapy on cell growth
Endocrine-sensitive and LTED BC cell lines retaining
ER expression and with varying levels of EGFR,
ERBB2, ERBB3, and FRAP1 expression [21] and
differing PIK3CA, ERBB2, and ESR1 mutation status
(Additional file 1: Figure S1a, b) were assessed for
their sensitivity to escalating doses of RAD001
(Fig. 2a) or neratinib (Fig. 2b) in the presence or
absence of E2. The addition of RAD001 to wt cell
lines in the absence of E2 showed minimal additional
anti-proliferative activity compared with E deprivation
alone. Contrastingly, in the presence of E2, RAD001
caused a concentration-dependent decrease in prolif-
eration in all wt cell lines tested. Overall, even at the
highest concentration of RAD001 (50 nM), the
anti-proliferative effect was inferior to that seen with
E deprivation alone. Contrastingly, all LTED models
showed a concentration-dependent decrease in prolif-
eration in the absence of E2 with varying degrees of
sensitivity. It is noteworthy that MCF7-LTED and
SUM44-LTED, which harbour an ESR1Y537S mutation,
appeared most sensitive with IC50 values of 1.5 and
0.5 nM, respectively (Fig. 2a and Additional file 1:
Figure S1c).
Escalating concentrations of neratinib caused a hor-
metic (bell shaped) proliferation curve in all the wt cell
lines tested in the absence of E2, with mid-range doses
causing an approximate two- to threefold increase in
proliferation. IC50 values for neratinib were not achieved
in this setting (Fig. 2b and Additional file 1: Figure S1d).
LTED derivatives in the absence of E2 showed IC50
values of 900 nM for MCF7-LTED and SUM44-LTED
and 400 nM for HCC1428-LTED. The addition of E2
increased the sensitivity of all wt cell lines, with
wt-MCF7 having the lowest recorded IC50 (300 nM)
(Fig. 2b and Additional file 1: Figure S1d).
We subsequently assessed the interaction between
RAD001 or neratinib with escalating doses of 4-OHT
and ICI (Additional file 2: Figure S2 and Additional file 3:
Figure S3). In the presence of exogenous E2, ICI and
4-OHT caused a concentration-dependent decrease in
proliferation in all wt and LTED cells. For all cell lines
tested, RAD001 enhanced the sensitivity to 4-OHT and
ICI with the exception of the HCC1428-LTED, in which
no further anti-proliferative effect was detected when
RAD001 was combined with 4-OHT (Additional file 2:
Figure S2b). Similar responses were observed when nerati-
nib was combined with 4-OHT or ICI, with the exception
of wt-HCC1428 with ICI and HCC1428-LTED with
4-OHT in which neratinib showed minimal impact, par-
ticularly at higher concentrations (> 1 nM) (Additional file 3:
Figure S3a, b).
Dual blockade of mTORC1 and ERBB signalling in
combination with endocrine therapy enhances
anti-proliferative effectiveness
As altered growth factor signalling has been associated
with mTORC1 blockade providing a route of resistance
to long-term inhibition of this kinase [9], we examined
the strategy of combining RAD001 with neratinib in the
presence of continued endocrine therapy. To assess this,
sub-optimal concentrations of each agent were com-
bined in the presence or absence of E2. For all the cells
lines tested, both in the presence and absence of E2, the
combination of RAD001 and neratinib showed a super-
ior anti-proliferative effect compared with either agent
alone (Fig. 3).
To assess the effect of combining mTORC1 and ERBB
suppression with endocrine therapy, cell lines were treated
with sub-optimal concentrations of RAD001 or neratinib
alone or in combination, with escalating doses of 4-OHT or
ICI. The combination of RAD001 and neratinib enhanced
the efficacy of both endocrine agents, particularly at the
lower concentration range (Additional file 4: Figure S4a, b).
Effect of the combination of RAD001 and neratinib on cell
signalling
To investigate the effect of RAD001 and neratinib alone
or in combination with endocrine agents on cellular sig-
nal transduction pathways, parental (endocrine-sensitive)
and LTED cell lines were treated with the drug combina-
tions indicated for 24 h ± E2, 4-OHT, or ICI (Fig. 4). As
expected, phosphorylation of S6 was dramatically
suppressed by RAD001 alone or in combination with
neratinib in all cell lines tested. Contrastingly, neratinib
caused cell line-specific effects on members of the ERBB
family. For instance, neratinib caused a significant
downregulation in total ERBB2 in all cell lines and re-
duced phosphorylated epidermal growth factor receptor
(EGFR) in MCF7-LTED, wt-SUM44, and wt-HCC1428,
as well as phosphorylated ERBB3 in wt-MCF7,
wt-SUM44, and HCC1428-LTED. Furthermore, RAD001
caused an upregulation of phosphorylated AKT in all
cell lines tested and increased phosphorylation of ERK1/
2 in wt-SUM44, and to a lesser degree in SUM44-LTED,
wt-HCC1428, and HCC1428-LTED, indicative of rapid
re-wiring previously associated with resistance to
mTORC1 inhibition [8–10]. It is noteworthy that, in the
majority of cell lines, the combination of RAD001 with
neratinib suppressed the upregulation of phosphorylated
AKT and ERK1/2 (Fig. 4).
To investigate the impact of RAD001 or neratinib
combined with 4-OHT or ICI versus the triple combin-
ation on cell cycle progression, we assessed the abun-
dance of pertinent cell cycle proteins. The combination
of endocrine therapy with either RAD001 or neratinib
decreased levels of phosphorylated RB, Cyclin D1, and
























































































































































































































































































































































































































































































Fig. 2 Anti-proliferative effect of a RAD001 and b neratinib in endocrine-resistant and -sensitive BC cell lines. Cells were treated in the absence or
presence of exogenous E2 (0.01 nM) and doubling concentrations of RAD001 or neratinib. Treatments were performed at day 1 and day 3 after
seeding. After 6 days of treatment, cell viability was analysed using a cell titer-glo assay. Data are expressed as fold-change relative to dextran
charcoal (DCC) control. Error bars represent mean ± SEM
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Fig. 3 (See legend on next page.)
Ribas et al. Breast Cancer Research  (2018) 20:44 Page 7 of 15
CDK4 to a greater extent than endocrine therapies alone.
However, as expected, the greatest degree of inhibition was
evident with triple combination concomitantly blocking
mTORC1, ERBB, and ER signalling, an effect most evident
with ICI (Fig. 4). No substantial increase in cleaved PARP
was evident, suggesting minimal impact on apoptosis.
Effect of RAD001 alone or in combination with neratinib
on ER transactivation
The majority of the patients who relapse on endocrine ther-
apy retain expression of ER. In-vitro data have shown that
ER can be phosphorylated in a ligand-independent manner,
circumventing the need for steroid hormones. Major path-
ways associated with this include ERBB/ERK1/2 and PI3K/
AKT/mTOR [6]. To assess whether interactions between
the drugs impacted on E-independent transactivation,
endocrine-sensitive and LTED cell lines were transiently
transfected with an ERE-luciferase reporter construct and
treated with either RAD001, neratinib, or the combination
with or without E2, 4-OHT, or ICI (Fig. 5a and
Additional file 5: Figure S5). Under E-deprived (DCC)
conditions, mimicking the effects of an AI, neratinib caused
a significant enhancement in ER/ERE-mediated transcrip-
tion compared with the vehicle control in all cell lines
tested (p ≤ 0.03), with the exception of SUM44-LTED
which showed a trend to significance (p = 0.1). RAD001
alone suppressed ER-mediated transcription to varying
extents across the cell lines. Most notably, wt-SUM44 and
SUM44-LTED together with HCC1428-LTED appeared
most sensitive, with a drop in ER-mediated transcription of
approximately 50% compared with the vehicle control. In
contrast, wt-MCF7 and their LTED derivatives, as well as
wt-HCC1428, were unaffected. Of note, the combination of
RAD001 and neratinib appeared to negate the
neratinib-driven increase in ER-mediated transcription in
several of the models (p ≤ 0.03). However, transactivation
remained higher than that seen with RAD001 alone, and
indeed the combination did not reduce the effect of nerati-
nib in wt-HCC1428 or MCF7-LTED.
To address the enhanced ER/ERE-mediated transactiva-
tion in response to neratinib, chromatin immunoprecipita-
tion was performed in wt-HCC1428 and HCC1428-LTED
cells, which showed differential responses to neratinib when
combined with RAD001 (Fig. 5a). ChIP analysis of ER
recruitment in wt-HCC1428 showed enrichment at the
TFF1 promoter in response to neratinib compared with the
vehicle control. The combination of RAD001 and neratinib
had no significant impact on recruitment, in keeping with
the ER/ERE-mediated transcription analysis (Fig. 5a, b).
Contrastingly, HCC1428-LTED showed enhanced recruit-
ment of ER in response to neratinib, which was significantly
reduced by the addition of RAD001 (p < 0.001) (Fig. 5b),
suggesting that context-specific impacts on ER-mediated
transcription were responsible for these events.
Sub-optimal concentrations of 4-OHT or ICI caused a
40–60% reduction in ER-transactivation in all cell lines,
with the exception of HCC1428-LTED in response to
4-OHT where the reduction did not meet statistical
significance. Similarly, SUM44-LTED, which harbours a
Y537S mutation in ESR1, showed no response to either
4-OHT or ICI. The combination of RAD001 or neratinib
with endocrine therapy showed no further reduction in
ER-mediated transcription compared with endocrine
therapy alone in all cell lines tested with the exception
of the SUM44 models. In this setting, RAD001 in
combination with 4-OHT or ICI caused a significant
reduction in ER-mediated transcription. However, the
addition of neratinib showed no impact and, indeed, the
triple combination impeded ER-mediated transactivation
to a similar degree as RAD001 when combined with
either endocrine agent. This suggests that wt-SUM44
and SUM44-LTED are particularly sensitive to cross-talk
between ER and mTORC1 signalling. Indeed, the com-
bination of 4-OHT with RAD001 significantly reduced
pERser167 and total ER (Additional file 5: Figure S5).
Effect of RAD001 alone or in combination with neratinib
and/or fulvestrant in vivo
To assess the effect of the drugs as monotherapies or com-
binations on tumour volume in vivo, mice were implanted
with MCF72a-LTED ER+ tumour cells, which grow inde-
pendently of exogenous E and model relapse on an AI
(details regarding generation of this model are shown in
Additional file 6: Figure S6a). Animals were treated with
vehicle, monotherapy (RAD001, neratinib or fulvestrant),
dual, or triple therapy combinations. The mean fold-change
in tumour volume for each treatment was expressed
relative to the start of treatment (Fig. 6a). Tumour volumes
(See figure on previous page.)
Fig. 3 Anti-proliferative effect of RAD001 (RAD), neratinib (Ner), or their combination in endocrine-resistant and -sensitive BC cell lines. Cell lines
were treated with vehicle or sub-optimal concentrations for each drug alone or in combination, both in the absence and presence of 0.01 nM
exogenous E2. After 6 days of treatment, cell viability was analysed using cell titer-glo and data expressed as fold-change relative to vehicle
control. Error bars represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Concentrations used in dextran charcoal (DCC): wt-MCF7 (0.75 nM
RAD001, 2000 nM neratinib); MCF7-LTED (0.75 nM RAD001, 500 nM neratinib); wt-SUM44 (0.75 nM RAD001, 2000 nM neratinib); SUM44-LTED
(0.4 nM RAD001, 500 nM neratinib); wt-HCC1428 (12.5 nM RAD001, 1200 nM neratinib); HCC1428-LTED (3 nM RAD001, 250 nM neratinib).
Concentrations used in E2: wt-MCF7 (1.5 nM RAD001, 200 nM neratinib); MCF7-LTED (1.5 nM RAD001, 300 nM neratinib); wt-SUM44 (0.37 nM
RAD001, 450 nM neratinib); SUM44-LTED (0.37 nM RAD001, 250 nM neratinib); wt-HCC1428 (1.5 nM RAD001, 500 nM neratinib); HCC1428-LTED
(3 nM RAD001, 250 nM neratinib)
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for the control vehicle group increased 1.8-times over the
treatment period (p = 0.1). All monotherapies caused a
reduction in tumour volume by day 41 compared with the
start of treatment (RAD001: 36%, p = 0.03; neratinib: 23%,
p = 0.6; fulvestrant: 37%, p = 0.03). Dual combination
therapies showed a further reduction in tumour volume
(RAD001 + neratinib: 73%, p = 0.03; RAD001 + fulvestrant:
72%, p = 0.004; neratinib + fulvestrant: 65%, p = 0.004).
Triple combination of RAD001, neratinib, plus fulvestrant
was the most effective, resulting in an 80% inhibition in
tumour growth (p = 0.008). Assessment of mouse weights
showed that the drug combinations had no significant
effect during the course of the study (Fig. 6b).
To assess dynamic changes in gene expression in
response to RAD001, neratinib, or the combinations with
fulvestrant, a second short-term xenograft study was
carried out followed by RNA-seq. Differentially expressed
genes were subjected to pathway analysis (Additional file 6:
Fig. 4 Effect of RAD001 (RAD), neratinib (Ner), or their combination with endocrine agents on cell signalling pathways governing cell cycle.
Endocrine-resistant and -sensitive BC cell lines were treated for 24 h with the drug combinations indicated. Whole-cell extracts were assessed
for expression on S6 kinase, ERK1/2, AKT, and ERBB signalling together with markers of cell cycle and apoptosis by immunoblotting. IC50 values
were used for RAD001 and neratinib together with standard concentrations of oestradiol (E2; 0.01 nM), 4-hydroxytamoxifen (4-OHT; 10 nM),
and fulvestrant (ICI; 1 nM) (with exception of HCC1428-LTED where 10 nM was used). ERBB pathways are highlighted in pink, ERK1/2 in blue,
mTORC1/AKT in green, and cell cycle in orange. wt-MCF7 (2 nM RAD001, 500 nM neratinib); MCF7-LTED (4 nM RAD001, 750 nM neratinib);
wt-SUM44 (3 nM RAD001, 700 nM neratinib); SUM44-LTED (3 nM RAD001, 700 nM neratinib); wt-HCC1428 (3 nM RAD001, 1000 nM neratinib);
HCC1428-LTED (10 nM RAD001, 500 nM neratinib)
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Figure S6b). As expected, RAD001 increased AKT and ERK
expression, which was reduced by the addition of neratinib.
ER expression was elevated with neratinib treatment com-
pared with RAD001 and fulvestrant. Notably, CoR expres-
sion was elevated in the dual (RAD001 plus neratinib) and
triple combination. Furthermore, global effects on
proliferation showed a greater reduction with the dual and
triple combinations compared with single agents. This was
further supported by the assessment of E2F target genes
(Additional file 6: Figure S6c). As expected, the triple com-
bination of RAD001, neratinib, and fulvestrant suppressed
the expression of cell cycle-associated genes (CCNE1,
b
a
Fig. 5 Effect of RAD001 (RAD), neratinib (Ner), or their combination on oestrogen receptor (ER)-mediated transactivation and recruitment of the
ER basal transcription machinery. a Cell lines were co-transfected with EREIItkLuc and pCH110 and treated for 24 h with RAD001 and neratinib
in the absence of E2 (DCC). Luciferase activity was normalized by β-galactosidase from triplicate wells and fold-changes expressed relative to the
DCC control. b ChIP analysis to determine the effect of neratinib, RAD001, or the combination on recruitment of ER to the TFF1 promoter in
wt-HCC1428 and HCC1428-LTED. Error bars represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Concentration used for transactivation assay
and ChIP: wt-MCF7 (2 nM RAD001, 500 nM neratinib); MCF7-LTED (4 nM RAD001, 650 nM neratinib); wt-SUM44 (3 nM RAD001, 700 nM neratinib);
SUM44-LTED (3 nM RAD001, 700 nM neratinib); wt-HCC1428 (3 nM RAD001, 700 nM neratinib); HCC1428-LTED (10 nM RAD001, 300 nM neratinib).
ns not significant
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CCNL1, CDK3, CDK7, and CDK9) when compared with
RAD001 alone or in combination with neratinib, in keeping
with the longer-term xenograft study (Additional file 7:
Figure S7a). Based on the pathway analysis, we used GSEA
to assess the dynamic changes in EGFR/ERBB2 signalling
after blockade with neratinib, RAD001, or the combina-
tions. Neratinib reduced the expression of genes associated
with EGF/EGFR activation of ERK signalling [22] (p =
0.004) (Fig. 6c); contrastingly, RAD001 significantly induced
expression of this gene set (p = 0.03) (Fig. 6d), an observa-
tion in support of rapid re-wiring associated with resistance
to mTORC1 inhibition. As expected, the combination of
neratinib and RAD001 significantly reduced expression of
the EGFR/ERK gene set (p = 0.003) (Fig. 6e). The addition
of fulvestrant to the double combination showed a further
trend in the reduction of this (p = 0.09) (Fig. 6f). Finally,
assessment of fulvestrant alone or in combination with
RAD001 showed no impact on EGFR/EGF-regulated genes;
however, the addition of neratinib significantly reduced the
EGFR/ERK gene set (p < 0.0001) (Additional file 7: Figure
S7b). Taken together, this suggests that the addition of
neratinib negates the EGF/EGFR feedback loop, providing
further support for the anti-proliferative effect seen with
the triple combination and highlighting the potential utility
of concomitantly targeting three cellular signalling nodes.
Discussion
In-vitro and in-vivo analysis of tumours that are resistant
to endocrine therapy suggests complex interplay between
cell signalling molecules, which cooperate to govern es-
cape mechanisms. Treatment with small molecule inhibi-
tors of pertinent pathways may provide clinical benefit.
For instance, recent studies have shown that blockade of
mTORC1 signalling in combination with AI therapy
causes a marked increase in PFS in patients with
c d e f
a b
Fig. 6 Effect of RAD001 (RAD) and neratinib (Ner) alone or in combination with endocrine therapy in vivo. a Long-term study assessing the
relative mean changes in tumour volume over 41 days of treatment and b effect of drug regimes on animal weight. Error bars represent mean ±
SEM (n = 7–9 animals per group). RAD001, 2 mg/kg; neratinib, 40 mg/kg; fulvestrant (ICI), 5 mg/kg. c–f GSEA enrichment plots for 198 genes
known to be induced by sustained activation of ERK in response to EGF activity. Plots show the profile of the running Enrichment Score and
positions of GeneSet Members on the Rank Ordered List for rank gene lists generated from the comparison of c neratinib vs. vehicle (Veh),
d RAD001 vs. vehicle, e RAD001 + neratinib vs. RAD001, and f RAD001 + neratinib + ICI vs. RAD001 + neratinib
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metastatic ER+ BC (BOLERO-2) [7]; however, relapse re-
mains a significant clinical issue.
To identify potential pathways attributed to the lack of
response to RAD001, we previously carried out a molecular
study in cell lines adapted to LTED, modelling the patient
cohort on the BOLERO-2 study. We showed that RAD001
induced a feedback loop via ERBB2/3, which could potenti-
ate resistance [9]. In further support of this, Carracedo and
colleagues [10] showed a similar upregulation of ERK1/2 in
response to mTORC1 inhibition. Furthermore, studies using
ERBB inhibitors have highlighted resistance pathways via
upregulation of PI3K/mTORC/AKT signalling [23, 24],
suggesting a high degree of cross-talk between these two
pivotal cellular signal transduction pathways. In addition,
both PI3K/mTORC/AKT and ERK1/2 have been implicated
in the ligand-independent activation of ER, leading to resist-
ance to endocrine therapy [6]. Based upon these observation,
we hypothesised that simultaneous blockade of all three
cellular nodes may provide potential benefit in circumventing
the resistance seen with individual therapies. To test this
hypothesis, we assessed the combination of neratinib, a
pan-ERBB inhibitor, with the mTORC1 inhibitor, RAD001,
in the presence of various endocrine agents in models
mimicking endocrine-sensitive and AI-resistant disease.
Surprisingly, treatment of endocrine-sensitive BC cells
with neratinib in the absence of exogenous E2 generated
a hormetic response curve, with a lower concentration
of the drug causing a marked increase in proliferation
and associated ER-mediated transactivation. Previous
clinical studies have reported a mixed benefit of the
combination of AI with EGFR or ERBB2 blockade in
primary or naive advanced BC, and in some cases have
shown a trend towards poorer outcome [25, 26]. Fur-
thermore, this observation is not only evident with tar-
geted EGFR and ERBB2 RTKs but also with pan-ERBB
inhibitors, such as AZD8931, in which a recent phase II
randomised study in combination with an AI in women
with endocrine-naive advanced BC provided no benefit
compared with anastrozole alone and did not delay
endocrine resistance in this patient population [27]. Not-
ably, treatment of LTED cell lines also showed enhanced
ER/ERE-mediated transcription and recruitment of ER
to target promoters in response to neratinib. However,
in contrast to the parental cell lines, proliferation
decreased. The decrease in proliferation is in keeping
with clinical studies, which suggest that patients who
have acquired resistance to endocrine therapy via upreg-
ulation of EGFR/ERBB2 may benefit from pan-ERBB
inhibition, as they become more reliant on growth factor
signalling as the mitogenic driver [26].
In contrast to E deprivation, the combination of neratinib
with 4-OHT or ICI showed an enhanced anti-proliferative
effect in the majority of parental cell lines. However,
although the combination outperformed either treatment
alone at the concentrations tested, the magnitude of benefit
was less than would be expected from an additive benefit
from either treatment alone. These data are in keeping with
previous in-vitro, as well as clinical, studies assessing the
combination of EGFR blockade with gefitinib to delay the
onset of endocrine resistance [28, 29]. The mechanism
underlying this remains unclear, but in-vitro studies suggest
that tamoxifen-bound ER binds co-repressor molecules
allowing the ERBB2 promoter to sequester SRC1 and AIB1,
leading to transcription of ERBB2 and potentially providing
the target for RTK inhibition [30].
Treatment with RAD001 showed differential effects on
cell proliferation. Most notably, the LTED derivatives
showed lower IC50 values compared with their parental cell
lines with the exception of HCC1428. PIK3CA mutation
status was not a governing factor of sensitivity, as both
SUM44 and HCC1428 harbour the wt gene. Wt-SUM44 in
the absence of exogenous E2 showed no response to
RAD001; however, this was attributed to the fact that,
under E-deprived conditions, the majority of cells are in cell
cycle arrest and as such further perturbation provides little
effect. This was confirmed by the observation in the pres-
ence of E2 where the IC50 was approximately 3 nM, similar
to that seen in MCF7-LTED. These data again show that
mutation status is not the governing feature of sensitivity,
and that cellular context remains more informative, in
keeping with the translational study of BOLERO-2 which
showed that PIK3CA mutations were not in themselves
predictive of clinical benefit to mTORC1 inhibitors [31].
Treatment with RAD001 decreased ER-mediated transcrip-
tion as a result of reduced S6 kinase activity and subsequent
phosphorylation of ERser167, which was particularly notable
in wt-SUM44 and their LTED derivative. Allosteric inhib-
ition of mTORC1 led to an increase in phosphorylated
AKT, indicative of the previously observed S6 feedback loop
[8]. Furthermore, in certain cell lines, ERK1/2 was also
elevated. This may indicate that phospho-ERK activation
following mTORC1 inhibition occurs via cross-talk with
the PI3K-RAS signalling pathway [10]. In selected cell lines,
evidence suggested that enhanced ERBB signalling may be
responsible for the observed ERK activation. Indeed, GSEA
analysis showed that RAD001 increased expression of EGF/
EGFR-associated genes which was significantly suppressed
by the addition of neratinib. In keeping with this, our
in-vivo study showed concordant data in which the triple
combination significantly reduced tumour volume.
Taken together, these data support the combination of
mTORC1 blockade with inhibition of ERBB signalling and
ER function in ER+ BC, highlighting the potential clinical
utility. Further support for the dual blockade of both
mTORC1 and ERBB signalling comes from a recent phase
I clinical trial piloting the combination of neratinib with
temsirolimus, in which antitumoral activity in patients
with advanced BC was evident [32].
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Conclusions
In conclusion, our results provide support for the combin-
ation of RAD001 together with neratinib and endocrine
therapy to re-sensitise endocrine-resistant tumours to the
anti-proliferative effects of endocrine therapy. Most notably,
the combination with ICI, disabling both the ER and AKT
axis, appeared superior. Furthermore, even within this
restricted panel of cell lines, the heterogeneity of response
highlights the need to identify common adaptive nodes.
Additional files
Additional file 1: Figure S1. IC50 values for the anti-proliferative effect
of RAD001 and neratinib in relation to the ESR1, ERBB2, and PIK3CA
mutational status in endocrine-resistant and -sensitive BC cell lines. (a)
Mutational or wt status is depicted in grey and white, respectively, for
ESR1, ERBB2, and PIK3CA. (b) Varying degrees of expression of genes
encoding proteins targeted by fulvestrant, neratinib, and RAD001
showing heterogeneity in the cell lines tested. (c,d) Cells were treated
in the absence or presence of exogenous oestradiol (E2) (0.01 nM) and
doubling concentrations of (c) RAD001 or (d) neratinib. Treatments were
performed at day 1 and day 3 after seeding. After 6 days of treatment,
cell viability was analysed using a cell titer-glo assay and IC50 values were
plotted. (PDF 156 kb)
Additional file 2: Figure S2. Anti-proliferative effect of RAD001 in
combination with endocrine agents (a) 4-OHT and (b) ICI. Endocrine-
resistant and -sensitive BC cell lines were treated with a combination of
RAD001 (3 nM) and increasing concentrations of (a) 4-OHT or (b) ICI for
6 days with media change at day 3. Cell viability was analysed using a
cell titer-glo assay. Data are expressed as fold-change relative to vehicle
control. Error bars represent mean ± SEM. (PDF 196 kb)
Additional file 3: Figure S3. Anti-proliferative effect of neratinib in
combination with endocrine agents (a) 4-OHT and (b) ICI. Endocrine-
resistant and -sensitive BC cell lines were treated with a combination
of neratinib (500 nM in wt-MCF7 and MCF7-LTED; 700 nM in wt-SUM44,
SUM44-LTED, and wt-HCC1428; 300 nM in HCC1428-LTED) and increasing
concentrations of (a) 4-OHT or (b) ICI for 6 days with media change at
day 3. Cell viability was analysed using a cell titer-glo assay. Data are
expressed as fold-change relative to vehicle control. Error bars represent
mean ± SEM. (PDF 195 kb)
Additional file 4: Figure S4. Anti-proliferative effect combination of
RAD001 and neratinib together with endocrine agents (a) 4-OHT and
(b) ICI. Endocrine-resistant and -sensitive BC cell lines were treated with
a combination of RAD001 and neratinib and increasing concentrations of
(a) 4-OHT or (b) ICI for 6 days with media change at day 3. Cell viability
was analysed using a cell titer-glo assay. Data are expressed as fold-change
relative to vehicle control. Error bars represent mean ± SEM. wt-MCF7
(1.5 nM RAD001; 200 nM neratinib); MCF7-LTED (1.5 nM RAD001; 300 nM
neratinib); wt-SUM44 (0.37 nM RAD001; 450 nM neratinib); SUM44-LTED
(0.37 nM RAD001; 250 nM neratinib); wt-HCC1428 (1.5 nM RAD001; 500 nM
neratinib); HCC1428-LTED (3 nM RAD001; 250 nM neratinib). (PDF 208 kb)
Additional file 5: Figure S5. Effect of RAD001, neratinib, or their
combination with endocrine agents on ER-mediated transactivation and
ER signalling. Cell lines were co-transfected with EREIItkLuc and pCH110,
and treated for 24 h with the drug combinations indicated. IC50 values
were used for RAD001 and neratinib together with standard concentrations
of E2 (0.01 nM), 4-OHT (0.1 nM), and ICI (0.1 nM). Luciferase activity was
normalized by β-galactosidase from triplicate wells and fold-changes
expressed relative to the E2 control. Error bars represent mean ± SEM.
*p< 0.05; **p< 0.01; ***p< 0.001. wt-MCF7 (2 nM RAD001; 500 nM neratinib);
MCF7-LTED (4 nM RAD001; 650 nM neratinib); wt-SUM44 (3 nM RAD001;
700 nM neratinib); SUM44-LTED (3 nM RAD001; 700 nM neratinib); wt-
HCC1428 (3 nM RAD001; 700 nM neratinib); HCC1428-LTED (10 nM RAD001;
300 nM neratinib). Western blot was used to assess changes in phosphorylation
of the ER in response to RAD001, neratinib, or their combination together with
endocrine agents. IC50 values were used for RAD001 and neratinib together
with standard concentrations of E2 (0.01 nM), 4-OHT (10 nM), and ICI (1 nM)
(with the exception of HCC1428-LTED where 10 nM was used). wt-MCF7
(2 nM RAD001; 500 nM neratinib); MCF7-LTED (4 nM RAD001; 750 nM
neratinib); wt-SUM44 (3 nM RAD001; 700 nM neratinib); SUM44-LTED
(3 nM RAD001; 700 nM neratinib); wt-HCC1428 (3 nM RAD001; 1000 nM
neratinib); HCC1428-LTED (10 nM RAD001; 500 nM neratinib). (PDF 1240 kb)
Additional file 6: Figure S6. Assessment of dynamic changes in gene
expression in response to RAD001, neratinib, or the combinations with
fulvestrant. (a) MCF72a cells, which were previously engineered to
express aromatase (CYP19) [33] were implanted into ovariectomised mice
under androstenedione support. In this setting, MCF72a cells convert
androstenedione in to oestrogen to drive proliferation. Once tumours
developed, androstenedione was withdrawn. After a lag phase, tumour
growth occurred synonymous with ligand independence. Assessment of
the MCF72a-LTED showed continued expression of ER and proliferation
in the absence of exogenous oestrogen providing a model of AI relapse.
(b) Changes to gene expression (log2 difference drug – vehicle) as detected
by RNA-seq for five drug combinations (neratinib, RAD001, ICI, neratinib +
RAD001, and neratinib + RAD001 + ICI) were mapped to KEGG pathway
graphs using Pathview (https://bioconductor.org/packages/release/bioc/
html/pathview.html). Genes with a fold-change greater than 50% compared
with vehicle in any condition were selected in order to expand the list of
differentially expressed genes, allowing the identification of subtle changes
in gene expression; for example, kinases or transcription factors that might
have significant impact on downstream gene expression. A heatmap for
each gene in shown. (c) Assessment of expression of E2F target genes in
response to neratinib and RAD001. (PDF 1861 kb)
Additional file 7: Figure S7. Assessment of dynamic changes in
expression of cell cycle regulatory genes. (a) Log2 differences in CCNE1,
CCNL1, CDK3, CDK7, and CDK9 gene expression following treatment with
RAD001, RAD001 + neratinib, and RAD001 + neratinib + fulvestrant (ICI),
compared with vehicle. (b) GSEA enrichment plots for 198 genes known
to be induced by sustained activation of ERK in response to EGF activity.
Plots show the profile of the running Enrichment Score and positions of
GeneSet Members on the Rank Ordered List for rank gene lists generated
from the comparison of: ICI vs. vehicle; neratinib + ICI vs. ICI; RAD001 + ICI
vs. ICI; and RAD001 + neratinib + ICI vs. RAD001 + ICI. (PDF 721 kb)
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